Prevention of Hepatitis C Virus (HCV) and HIV-1 Co-Infections
A collaborative project financed by the EC Framework Programme 7
GSK is a world leader in innovation and the manufacture of vaccines. We pioneer advances in vaccines against preventable diseases, to help reduce the impact of disease on the world’s population.
Our scientific expertise helps us to provide a broad range of vaccines solutions. Fostering innovation with external partners lies at the heart of our business model.
Based on the adenovector technology developed by Okairos that has shown stimulation of an antigen-specific CD8+T-cell response in pre-clinical and clinical trials, GSK will develop new vaccines that contrary to conventional vaccines, will induce a potent antigen-specific CD8+ T cell response.
GSK has an extensive track record of partnering including over 100 current collaborations worldwide with large pharmaceutical companies, small biotech businesses, consortia, charities and academia (graduate and post-doctoral research programs).
Developing vaccines with unique qualities, challenging more diseases, improving the efficacy of current vaccines, and helping clients to meet their immunisation objectives, are all principles which have made us a leader in this field. We welcome new proposals and initiatives for future collaborations that would be aligned with our mission. Please feel free to contact us at firstname.lastname@example.org.